

Douglas I Lin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7231570/publications.pdf>

Version: 2024-02-01

76
papers

1,529
citations

394421

19
h-index

330143

37
g-index

77
all docs

77
docs citations

77
times ranked

2366
citing authors

#	ARTICLE	IF	CITATIONS
1	Phosphorylation-Dependent Ubiquitination of Cyclin D1 by the SCFFBX4- $\hat{\pm}$ B Crystallin Complex. <i>Molecular Cell</i> , 2006, 24, 355-366.	9.7	321
2	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). <i>Nature Communications</i> , 2021, 12, 2487.	12.8	116
3	Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication. <i>Genes and Development</i> , 2007, 21, 2908-2922.	5.9	115
4	Evidence for a Dualistic Model of High-grade Serous Carcinoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 287-293.	3.7	96
5	Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. <i>European Urology</i> , 2016, 70, 516-521.	1.9	90
6	Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. <i>European Urology</i> , 2018, 73, 71-78.	1.9	87
7	A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases. <i>Modern Pathology</i> , 2021, 34, 252-263.	5.5	78
8	SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association. <i>Modern Pathology</i> , 2019, 32, 1675-1687.	5.5	56
9	Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss. <i>Gynecologic Oncology</i> , 2020, 157, 357-366.	1.4	41
10	Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type. <i>Gynecologic Oncology</i> , 2017, 147, 626-633.	1.4	37
11	Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Network Open</i> , 2022, 5, e225394.	5.9	37
12	Automated clear cell renal carcinoma grade classification with prognostic significance. <i>PLoS ONE</i> , 2019, 14, e0222641.	2.5	35
13	Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts. <i>Gynecologic Oncology</i> , 2020, 157, 106-114.	1.4	29
14	Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA. <i>Oncology</i> , 2020, 98, 905-912.	1.9	27
15	Oncogenic c-terminal cyclin D1 (CCND1) mutations are enriched in endometrioid endometrial adenocarcinomas. <i>PLoS ONE</i> , 2018, 13, e0199688.	2.5	25
16	Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors. <i>Gynecologic Oncology</i> , 2018, 151, 401-406.	1.4	23
17	Molecular profiling of mesonephric and mesonephric-like carcinomas of cervical, endometrial and ovarian origin. <i>Gynecologic Oncology Reports</i> , 2020, 34, 100652.	0.6	22
18	Comparing histologic evaluation of prostate tissue using nonlinear microscopy and paraffin H&E: a pilot study. <i>Modern Pathology</i> , 2019, 32, 1158-1167.	5.5	21

#	ARTICLE	IF	CITATIONS
19	Vulvar Squamous Cell Carcinoma: Comprehensive Genomic Profiling of HPV+ Versus HPV- Forms Reveals Distinct Sets of Potentially Actionable Molecular Targets. <i>JCO Precision Oncology</i> , 2020, 4, 647-661.	3.0	21
20	Clinicopathological and genomic characterization of BCORL1-driven high-grade endometrial stromal sarcomas. <i>Modern Pathology</i> , 2021, 34, 2200-2210.	5.5	20
21	Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma. <i>Modern Pathology</i> , 2021, 34, 1425-1433.	5.5	19
22	Amplification of the NSD3-BRD4-CHD8 pathway in pelvic high-grade serous carcinomas of tubo-ovarian and endometrial origin. <i>Molecular and Clinical Oncology</i> , 2017, 7, 301-307.	1.0	18
23	Amplification of the bromodomain-containing protein 4 gene in ovarian high-grade serous carcinoma is associated with worse prognosis and survival. <i>Molecular and Clinical Oncology</i> , 2015, 3, 1291-1294.	1.0	16
24	Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions. <i>BJU International</i> , 2020, 125, 739-746.	2.5	14
25	Targeted Screening With Combined Age- and Morphology-Based Criteria Enriches Detection of Lynch Syndrome in Endometrial Cancer. <i>International Journal of Surgical Pathology</i> , 2016, 24, 297-305.	0.8	13
26	Circulating Cell-Free DNA Yield and Circulating-Tumor DNA Quantity from Liquid Biopsies of 139 Cancer Patients. <i>Clinical Chemistry</i> , 2021, 67, 1554-1566.	3.2	13
27	Mixed Endometrioid Adenocarcinoma and Malignant Adenosarcoma of the Uterus and Ovary. <i>American Journal of Surgical Pathology</i> , 2021, 45, 374-383.	3.7	12
28	TNS1- ALK Fusion in a Recurrent, Metastatic Uterine Mesenchymal Tumor Originally Diagnosed as Leiomyosarcoma. <i>Acta Medica Academica</i> , 2019, 48, 116.	0.8	12
29	Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary. <i>Modern Pathology</i> , 2021, 34, 983-993.	5.5	11
30	Hepatocellular Adenoma of the Placenta With Updated Immunohistochemical and Molecular Markers. <i>International Journal of Surgical Pathology</i> , 2016, 24, 640-643.	0.8	10
31	Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups. <i>Gynecologic Oncology</i> , 2022, 164, 558-565.	1.4	9
32	Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas. <i>Oncologist</i> , 2021, 26, 375-382.	3.7	8
33	Pan-cancer landscape of CD274 (PD-L1) rearrangements in 283,050 patient samples, its correlation with PD-L1 protein expression, and immunotherapy response. <i>Cell</i> , 2021, 9, e003550.		8
34	Improved survival associated with somatic PIK3CA mutations in copy-number low endometrioid endometrial adenocarcinoma. <i>Oncology Letters</i> , 2015, 10, 2743-2748.	1.8	7
35	CDKN2C-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53/RB1-Wild-Type Tumor With Frequent CIC Genomic Alterations and 1p/19q-Codeletion. <i>JCO Precision Oncology</i> , 2020, 4, 955-971.	3.0	6
36	Endometrioid Tubal Intraepithelial Neoplasia (E-TIN) of the Fallopian Tube: A Case Series. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 552-557.	1.4	6

#	ARTICLE	IF	CITATIONS
37	<i>NF2</i> mutation-driven renal cell carcinomas (RCC): A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2020, 38, 726-726.	1.6	6
38	Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors. Gynecologic Oncology, 2021, 162, 728-734.	1.4	4
39	Primary versus metastatic intrahepatic cholangiocarcinoma: A comparative comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2020, 38, 578-578.	1.6	4
40	Clinical Implications of Genomic Loss of Heterozygosity in Endometrial Carcinoma. JCO Precision Oncology, 2021, 5, 1013-1023.	3.0	3
41	Differential genomic landscape of clinically advanced/metastatic chordomas (mChor) based on primary tumor site.. Journal of Clinical Oncology, 2020, 38, 11521-11521.	1.6	3
42	Clinically advanced penile (pSCC) and male urethral (uSCC) squamous cell carcinoma: A comparative genomic profiling (CGP) study.. Journal of Clinical Oncology, 2021, 39, 2-2.	1.6	2
43	Immunotherapy predictive biomarkers in metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2019, 37, 1023-1023.	1.6	2
44	FGFR2: A pan-genomic target.. Journal of Clinical Oncology, 2019, 37, 3099-3099.	1.6	2
45	PD-L1 expression, tumor mutational burden, and microsatellite instability status in 746 pancreas ductal adenocarcinomas.. Journal of Clinical Oncology, 2020, 38, 757-757.	1.6	2
46	HPV51-associated Leiomyosarcoma. American Journal of Surgical Pathology, 2022, 46, 729-741.	3.7	2
47	Landscape of fibroblast growth factor receptor (<i>FGFR</i>) genomic alterations (GA) in urothelial bladder cancer (UBC).. Journal of Clinical Oncology, 2022, 40, 4568-4568.	1.6	2
48	A sporadic gastric-type endocervical adenocarcinoma with endometrial involvement and bilateral ovarian metastasis, a case report. Gynecologic Oncology Reports, 2020, 32, 100572.	0.6	1
49	Genomic landscape of <i>MSH6</i> -mutated clinically advanced castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 5062-5062.	1.6	1
50	Clinically advanced pelvic squamous cell carcinomas (pSCC) in men and women: A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2021, 39, 3130-3130.	1.6	1
51	Metastatic penile (mPSCC), uterine cervical (mCSCC), and skin (mSSCC) squamous cell carcinomas: A comparative genomic profiling (CGP) study.. Journal of Clinical Oncology, 2019, 37, 4585-4585.	1.6	1
52	Primary tumor (p-bx) versus metastatic tumor (m-bx) tissue versus liquid biopsy (lb) in intrahepatic cholangiocarcinoma (IHCC): A comparative comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2020, 38, 4579-4579.	1.6	1
53	Comprehensive genomic profiling (CGP) in post-systemic treatment (Post) metastatic sites (MET) and pretreatment (Pre) primary tumors (PT) of metastatic prostate cancer (mPC).. Journal of Clinical Oncology, 2020, 38, 175-175.	1.6	1
54	Extra-mammary Paget's disease (EMPD) of the skin: A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2019, 37, 9591-9591.	1.6	1

#	ARTICLE	IF	CITATIONS
55	Increased tumor purity and improved biomarker detection using precision needle punch enrichment of pathology specimen paraffin blocks: Method validation and implementation in a prospective clinical trial.. Journal of Clinical Oncology, 2020, 38, 3622-3622.	1.6	1
56	Comprehensive genomic profiling (CGP) of histologic subtypes of urethral carcinomas (UrthCa).. Journal of Clinical Oncology, 2020, 38, 5087-5087.	1.6	1
57	Clinically aggressive malignancies associated with STK11 germline mutations (STK11Ca): A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2020, 38, 3558-3558.	1.6	1
58	OUP accepted manuscript. Oncologist, 2022, , .	3.7	1
59	Landscape of homologous recombination reversion mutations in gynecologic malignancies.. Journal of Clinical Oncology, 2022, 40, 5576-5576.	1.6	1
60	HHV-8 positive clinically advanced castrate-resistant prostate cancer (mCRPC): A potentially distinct molecular subset.. Journal of Clinical Oncology, 2021, 39, 163-163.	1.6	0
61	HPV-16 positive clinically advanced squamous cell carcinoma of the urinary bladder (mBSCC): A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2021, 39, 481-481.	1.6	0
62	Comprehensive molecular profiling of pleural mesothelioma according to histologic subtype.. Journal of Clinical Oncology, 2021, 39, 8555-8555.	1.6	0
63	Assessment of predictive biomarker prevalence in molecularly defined adult-type ovarian granulosa cell tumors.. Journal of Clinical Oncology, 2021, 39, 5567-5567.	1.6	0
64	Anal melanoma: A comparative comprehensive genomic profiling study.. Journal of Clinical Oncology, 2019, 37, 9566-9566.	1.6	0
65	Contrasting genomic profiles in post-systemic treatment metastatic sites (MET), pretreatment primary tumors (PT), and liquid biopsies (LB) of clinically advanced prostate cancer (PC).. Journal of Clinical Oncology, 2020, 38, 5534-5534.	1.6	0
66	Acquired RB1 mutations in estrogen receptor-positive (ER+) clinically advanced and metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2020, 38, 1053-1053.	1.6	0
67	Primary adult retroperitoneal sarcoma (RS): Comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2020, 38, 11541-11541.	1.6	0
68	Comprehensive genomic profiling (CGP) of histologic subtypes of urethral carcinomas (UrthCa).. Journal of Clinical Oncology, 2020, 38, 426-426.	1.6	0
69	Metastatic renal cell carcinoma (mRCC) in young patients: A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2020, 38, 727-727.	1.6	0
70	Expanding the use of targeted therapy for urothelial bladder cancer (UBC): Non-FGFR3 receptor tyrosine kinase (RTK) gene rearrangements (ReAr) and fusions (fus).. Journal of Clinical Oncology, 2022, 40, 550-550.	1.6	0
71	Association of RB1 mutational status with overall genomic landscape in neuroendocrine prostate cancer (NEPC).. Journal of Clinical Oncology, 2022, 40, 156-156.	1.6	0
72	Tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus taxane chemotherapy benefit in metastatic castration-resistant prostate cancer: A real-world biomarker study.. Journal of Clinical Oncology, 2022, 40, 162-162.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Impact of PD-L1 expression on conventional urothelial bladder carcinoma (UBC) genomic alteration (GA) profile.. Journal of Clinical Oncology, 2022, 40, 563-563.	1.6	0
74	Genomic classification of clinically advanced major genito-urinary cancers (GUca) based on methylthioadenosine phosphorylase (<i>MTAP</i>) genomic loss.. Journal of Clinical Oncology, 2022, 40, 164-164.	1.6	0
75	Comprehensive genomic profiling (CGP) of chromophobe renal cell carcinoma (chrRCC) compared with clear cell RCC (ccRCC): Impact of <i>FLCN</i> genomic alteration (GA) status.. Journal of Clinical Oncology, 2022, 40, 292-292.	1.6	0
76	Biomarker associations of immune checkpoint inhibitor versus chemotherapy effectiveness in first-line metastatic endometrial carcinomas: A real-world study.. Journal of Clinical Oncology, 2022, 40, 5596-5596.	1.6	0